Dimensional Fund Advisors LP Has $19.02 Million Position in MannKind Co. (NASDAQ:MNKD)

Dimensional Fund Advisors LP lifted its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 40.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,958,219 shares of the biopharmaceutical company's stock after acquiring an additional 855,261 shares during the period. Dimensional Fund Advisors LP owned approximately 1.07% of MannKind worth $19,022,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Jones Financial Companies Lllp lifted its holdings in shares of MannKind by 3,294.8% in the fourth quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 6,392 shares during the last quarter. Beirne Wealth Consulting Services LLC bought a new position in shares of MannKind in the fourth quarter worth about $66,000. Proficio Capital Partners LLC bought a new position in shares of MannKind in the fourth quarter worth about $70,000. Marshall Investment Management LLC bought a new position in shares of MannKind in the fourth quarter worth about $69,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of MannKind in the fourth quarter worth about $86,000. 49.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Wedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of MannKind in a report on Thursday, February 27th. Mizuho assumed coverage on shares of MannKind in a report on Thursday, April 10th. They issued an "outperform" rating and a $12.00 price objective for the company. Finally, StockNews.com upgraded shares of MannKind from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, MannKind presently has a consensus rating of "Buy" and an average price target of $10.00.

MannKind Stock Performance

Shares of MNKD stock traded down $0.12 during trading hours on Tuesday, hitting $4.69. 888,721 shares of the company were exchanged, compared to its average volume of 2,378,552. The firm has a market cap of $1.43 billion, a P/E ratio of 67.00 and a beta of 1.14. MannKind Co. has a fifty-two week low of $4.28 and a fifty-two week high of $7.63. The company has a 50 day simple moving average of $4.88 and a two-hundred day simple moving average of $5.81.

MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. The company had revenue of $78.35 million during the quarter, compared to the consensus estimate of $75.86 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The company's quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 EPS. As a group, sell-side analysts expect that MannKind Co. will post 0.1 EPS for the current fiscal year.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.